SMALL CELL LUNG CARCINOMA (SCLC)
Clinical trials for SMALL CELL LUNG CARCINOMA (SCLC) explained in plain language.
Never miss a new study
Get alerted when new SMALL CELL LUNG CARCINOMA (SCLC) trials appear
Sign up with your email to follow new studies for SMALL CELL LUNG CARCINOMA (SCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lung cancer: drug combo trial launches
Disease control OngoingThis study tests a new drug, BI 764532, combined with chemotherapy for adults with advanced small cell lung cancer that returned after prior treatment. The goal is to find the safest dose and see if the combo helps control the cancer. About 69 participants will receive the treatm…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 17, 2026 08:14 UTC
-
New hope for tough lung cancer: experimental drug joins standard care
Disease control OngoingThis study tests a new experimental drug called BI 764532 (obrixtamig) combined with standard chemotherapy and immunotherapy for adults with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. Pa…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
First human test of new cancer drug combo for Tough-to-Treat lung tumors
Disease control OngoingThis early-stage study is testing a new combination of two immunotherapy drugs, obrixtamig and ezabenlimab, for adults with advanced small cell lung cancer or related neuroendocrine tumors that have stopped responding to standard treatments. The main goal is to find the highest d…
Matched conditions: SMALL CELL LUNG CARCINOMA (SCLC)
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC